Royal Philips Electronics NV (PHIA.AE) said Wednesday it has reached an agreement with US-based GlyGenix Therapeutics Inc to explore the feasability of using ultrasound technologies for gene therapy.

MAIN FACTS:

-The collaboration will research the treatment of Glycogen Storage Disease Type 1a (GSD-1a) in preclinical studies.

-GlyGenix Therapeutics is based in Woodbridge, Connecticut.

-Philips doesn't provide financial details.

- By Amsterdam Bureau, Dow Jones Newswires; amsterdam@dowjones.com